Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
545 Leser
Artikel bewerten:
(2)

HYDROGEN REFUELING SOLUTIONS (HRS): HYMPULSION CHOOSES HRS FOR AN ORDER OF 2 HIGH-CAPACITY HYDROGEN STATIONS (HRS40) FOR THE ZERO EMISSION VALLEY (ZEV) PROGRAM

Finanznachrichten News

HYMPULSION CHOOSES HRS FOR AN ORDER OF 2 HIGH-CAPACITY HYDROGEN STATIONS (HRS40)

FOR THE ZERO EMISSION VALLEY (ZEV) PROGRAM

Grenoble, March 13, 2023 - HRS , European designer and manufacturer of hydrogen refueling stations, announces that it has received a request to move upmarket, with the supply of 2 stations HRS40 (40 kg/hour or 1 ton/day), from the company HYmpulsion, in charge of the Zero Emission Valley ("ZEV") project.

The Zero Emission Valley project aims to develop a profitable and sustainable carbon-free sector in the Auvergne-Rhône-Alpes region by rolling out infrastructure for green hydrogen production, storage, and distribution, as well as providing hydrogen-powered vehicles.

The project involves green hydrogen production alongside the deployment of 18 hydrogen stations, 450 zero-emission fuel cell light vehicles and around 115 buses, trucks and coaches by 2024. The aim of the project is for the Auvergne-Rhône-Alpes region to become the pioneer in French hydrogen mobility and one of the first carbon-neutral areas in Europe, while contributing to the creation of profitable models that can be reproduced on a European scale.

To date, the project has unveiled three stations, including the Saint-Priest station manufactured by HRS. This HRS14 station (14 kg/hour) currently represents the largest daily flow capacity in the ZEV network. In addition, a next deployment is planned in Aubenas (07) with a HRS14 station (14 kg/hour) previously ordered.

In this context, HYmpulsion will accelerate the deployment of its distribution network in the coming months and chooses HRS to supply its first larger capacity stations by ordering two HRS40 stations (40 kg/hour or 1 ton/day), which will be installed in Lyon Saint-Exupéry (69) and in Malataverne (26).

Hassen Rachedi, Founding Chairman & CEO, said: "HRS is delighted to become more involved in the ZEV program. HYmpulsion is a pioneer in French hydrogen mobility development and our place is alongside theirs to step up the use of this carbon-free energy for transport decarbonization. We are currently the only French company capable of manufacturing the large-capacity stations required for the mass deployment of hydrogen mobility. Therefore, it is only natural for HRS and HYmpulsion to be working together again. There are still some stations yet to be delivered as part of the ZEV program and we believe we can provide our extensive know-how to help build one of Europe's boldest hydrogen programs."

HYmpulsion Chairman Thierry Raevel said: "As Chairman of HYmpulsion, I am delighted to continue working with HRS. The company's technical expertise, based on its research and innovation capacities, combined with its operational excellence driven by Chairman and CEO Hassen Rachedi, makes HRS one of HYmpulsion's major partners. I am also pleased to announce to Mr. Hassen Rachedi today our order for two HRS40 stations. Together we will help promote the seamless development of the environment while creating jobs in the region."

ABOUT HRS

Founded in 2004, Hydrogen-Refueling-Solutions (HRS), formerly TSM, is pioneer in hydrogen mobility. European designer and manufacturer of hydrogen refueling stations, for over ten years, the Company has been committed to reducing transport emissions.

Thanks to its unique experience and know-how, HRS has developed a complete range of hydrogen refueling stations for all types of fuel cell vehicles that is perfectly suited to the needs of a fast-growing European market. At its Champ-sur-Drac site, HRS has mass production capacities that enable it to assemble up to 60 units per year in record time, in as little as 8 weeks.

The Company posted 2021/2022 revenue of €17.0 million. As of June 30, 2022, the company had 78 employees. (ISIN code: FR0014001PM5 - ticker symbol: ALHRS).

CONTACTS

Relations investisseurs
ACTUS finance & communication
Grégoire SAINT-MARC
hrs@actus.fr
00 33 1 53 67 36 94
Financial press relations
ACTUS finance & communication
Anne Catherine BONJOUR
hrs-presse@actus.fr
00 33 1 53 67 36 93
Corporate press relations
ACTUS finance & communication
Déborah Schwartz
hrs-presse@actus.fr
00 33 1 53 67 36 35
------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nWmfYJacZ5jJyW9xZchonGhnbm9omJPHZWiYk5JtYpvJmHKRyZlnmJmXZnBpnW5u
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-78898-2023-13-03-commande-zev-vf_en.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2023 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.